The Overall Quality Control of Xianling Gubao Capsules Based on HPLC-UVD-ELSD Fingerprint and Simultaneous Determination of Main Representative Components
YAO Zhi-hong1,2, ZHENG Yuan-ru1,2, ZHOU Xian-qiang1,2, LI Meng-sen1,2, CHEN Zi-lin1,2, DAI Yi1,2, YAO Xin-sheng1,2
1. Institute of Traditional Chinese Medicine & Natural Products, Jinan University, Guangzhou 510632, China; 2. Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drug Research, College of Pharmacy, Jinan University, Guangzhou 510632, China
Abstract��OBJECTIVE To establish the fingerprint of Xianling Gubao Capsules (XLGB) by multi-wavelength HPLC-UVD-ELSD and determine the main representative components simultaneously, in order to provide reference for the overall quality control of XLGB.METHODS The separation was developed on Poroshell 120 EC-C18 column (4.6 mm��100 mm, 2.7 ��m) by gradient elution with methanol-water at 240, 270 and 334 nm, the temperature of drift tube was maintained at 105 �� and the carrier gas flow rate was 2.0 L��min-1. An HPLC-UVD-ELSD fingerprint of XLGB was set up, and 15 batches of XLGB were evaluated by similarity assay. Furthermore, the contents of the main representative components were determined on the premise of small disparities between batches. RESULTS The multi-wavelength HPLC-UVD-ELSD fingerprint of XLGB was established with good separation, and six chemical components were determined simultaneously. Thirty-one main characteristic peaks from six herbs of XLGB were chemically identified and 26 main characteristic peaks were assigned to individual herbs. The similarity of 15 batches of XLGB was about 0.943 to 0.997. Moreover, good linear relationships were found (r=0.999 0-0.999 6), and the average recovery rates were 98.5%-104.9%. CONCLUSION The method can be used for the overall quality control of XLGB with good specificity and high efficiency and is close to the actual production, which is promising to be further improved to be used as an industry internal control standard.
Ҧ־��, ֣Զ��, ����ǿ, ����ɭ, ������, ����, Ҧ����. ����HPLC-UVD-ELSDָ��ͼ�����Ҫ����ɷ�ͬʱ������������������ʿ��о�[J]. �й�ҩѧ��־, 2018, 53(17): 1504-1510.
YAO Zhi-hong, ZHENG Yuan-ru, ZHOU Xian-qiang, LI Meng-sen, CHEN Zi-lin, DAI Yi, YAO Xin-sheng. The Overall Quality Control of Xianling Gubao Capsules Based on HPLC-UVD-ELSD Fingerprint and Simultaneous Determination of Main Representative Components. Chinese Pharmaceutical Journal, 2018, 53(17): 1504-1510.
WU J J, WEN L P, WU Y G, et al. Effects of Xianling Gubao capsules for the treatment of bone loss induced by glucocorticoid. China J Orthop & Trauma (�����), 2009, 22(3):193-195.
[2]
JIN J F, ZHANG J W. Clinical efficacy and safety evaluation of Xianling Gubao Capsule treatment of osteoporosis pain. Chin Arch Tradit Chin Med (�л���ҽҩѧ��), 2014, 32(12):3050-3052.
[3]
ZHU H M,QIN L,GARNERO P, et al. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis. Bone, 2010, 47(3):457-458.
[4]
HUANG D L. Research progress on Xianlinggubao capsule in treating osteoporosis. China J Chin Med (��ҽѧ��), 2013, 28(2):285-287.
[5]
TU F J. Study on the Anti-osteoporosis Material Basis of Traditional Chinese Medicine Prescription Xian-Ling-Gu-Bao . Shenyang:Shenyan Pharmacy University, 2011.
[6]
LI X L. Study on enhancing the quality standard of Epimedium brevicornu Maxim and Xianlinggubao capsule . Guiyang:Guiyang College of Traditional Chinese Medicine, 2010.
[7]
CHENG H, YAO Z H, DAI Y, et al. HPLC Fingerprint of Xianling Gubao Capsule, a TCM prescription. Chin Pharm J (�й�ҩѧ��־), 2013, 48(10):772-776.
[8]
HE L L, YAO Z H, WU X M, et al. UPLC-PDA Fingerprint of Xianling Gubao Capsules. Chin Pharm J (�й�ҩѧ��־), 2016, 51(18):1551-1556.
[9]
YAO Z H, QIN Z F, CHENG H, et al. Simultaneous quantification of multiple representative components in the Xian-Ling-Gu-Bao Capsule by ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. Molecules, 2017, 22(6):1-13.
[10]
WU X M. The study of fingerprint of XLGB for multiple characteristic components and their dynamic profile in target tissues . Guangzhou:Jinan University, 2015.
[11]
ZHU Y Y, ZHOU L. HPLC Determination of three steviol glycosides in Stevia rebaudiana Bertohi. Chin J Pharm Anal (ҩ�������־), 2014(1):184-189.
[12]
SHI Y. Research on concept formalization in the construction of the prescriptions ontology. J Mathematical Med (����ҽҩѧ��־), 2011, 24(5):575-577.
[13]
LIU Y. The determination of the content of astragaloside IV by ELSD. Sci Tech Dev Enterp (��ҵ�Ƽ��뷢չ), 2015(2):45-47.
2018, Vol. 53 
